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Abstract
With the rapid development of high-throughput technologies,
parallel acquisition of large-scale drug-informatics data pro-
vides huge opportunities to improve pharmaceutical research
and development. One significant application is the purpose
prediction of small molecule compounds, aiming to specify
therapeutic properties of extensive purpose-unknown com-
pounds and to repurpose novel therapeutic properties of FDA-
approved drugs. Such problem is very challenging since com-
pound attributes contain heterogeneous data with various fea-
ture patterns such as drug fingerprint, drug physicochemical
property, drug perturbation gene expression. Moreover, there
is complex nonlinear dependency among heterogeneous data.
In this paper, we propose a novel domain-adversarial multi-
task framework for integrating shared knowledge from mul-
tiple domains. The framework utilizes the adversarial strat-
egy to effectively learn target representations and models
their nonlinear dependency. Experiments on two real-world
datasets illustrate that the performance of our approach ob-
tains an obvious improvement over competitive baselines.
The novel therapeutic properties of purpose-unknown com-
pounds we predicted are mostly reported or brought to the
clinics. Furthermore, our framework can integrate various at-
tributes beyond the three domains examined here and can
be applied in the industry for screening the purpose of huge
amounts of as yet unidentified compounds. Source codes of
this paper are available on Github.
Introduction
Purpose prediction of small molecule compounds is crit-
ical in pharmaceutical research and development (R&D)
(Macarron et al. 2011). While considerable progress has
been achieved during the past decades, traditional de novo
strategy remains to be extremely costly, risky, and time con-
suming (DiMasi, Hansen, and Grabowski 2003), especially
for pharmaceutical companies who synthesize and accumu-
late huge amount of small molecule compound without a
definite therapeutic property. To conduct purpose predic-
tion economically attractive, low-risking, and time-saving,
drug-discovering strategies based on drug-informatics data
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Figure 1: Heterogeneous drug-informatics data. The at-
tributes of drugs vary significantly from each other, but un-
derlying complementary information exists among them.
and computational approaches have been introduced and ex-
hibits substantial improvement (Keiser et al. 2009; Boguski,
Mandl, and Sukhatme 2009).
It is a challenging problem to specify therapeutic proper-
ties of purpose-unknown compounds and to repurpose novel
therapeutic properties of FDA-approved drugs since each
kind of compound contains complicated attributes (See Fig.
1 as an example), such as drug fingerprint, drug physico-
chemical property, drug perturbation gene expression and so
on. Many researchers tried only chemical structure for pre-
diction (Ma, Chan, and Leung 2013; Haupt and Schroeder
2011; Xie et al. 2017; Wang, Clark, and Maayan 2016).
Nevertheless, Yildirim et al. pointed out that most drugs
with the same targets have different chemical structures
so that structure-based prediction seems not so convincing
(Yıldırım et al. 2007). Moreover, the constitution of each in-
dividual attribute varies significantly. For example, gene ex-
pression consists of over 10,000 genome-wide expressions
while the structural fingerprint is a kind of graphical repre-
sentation of arrangement of chemical bonds between atoms.
Besides, there is high level of dependency among different
attributes. For instance, drug fingerprint not only refers to
the inside spatial arrangement of atoms, also leads to vari-
ous physical and chemical properties. It turns out that these
complicated drug attributes yield heterogeneous drug data
consisting of correlated domains, and data patterns of which
vary significantly.
Most existing approaches for integrating drug-informatics
data from several domains were based on the linear combi-
nation. For example, Napolitano et al. constructed three drug
similarity networks based on drug structure, distance of drug
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targets in protein-protein interaction networks, and expres-
sion patterns of drug perturbations, then integrated datasets
by averaging three drug similarity measurements to predict
new therapeutic properties of drugs (Napolitano et al. 2013).
Wang et al. proposed a new algorithm, named PreDR, which
predicts unidentified drug-disease associations by taking the
maximums of three drug similarity matrices derived from
chemical structure, target protein sequence, and side effect
profile similarities (Wang et al. 2013). However, the per-
formance of these approaches reach a plateau because of
inefficient compatibility. Although some methods have im-
provements by integrating two data domains, they are barely
generalized to others, and the performance even degrades
when scale to more data domains. On the one hand, the in-
trinsic nonlinear patterns which possess better prospect for
inference would be ignored inevitably when linear combina-
tion. On the other hand, there are many overlap information
among data domains.
In the literature, joint learning representations of het-
erogeneous data is widely studied especially for speech
recognition and clinical endpoint prediction. The state-of-
the-art approaches are commonly extensions of recurrent
neural networks (RNNs) with the Long Short-term Mem-
ory (LSTM) units. RNNs are commonly used for model-
ing many kinds of temporal sequences and the correlations
among multiple data. It is nontrivial to apply to data with-
out time attribute, and the irregular data shapes are still
a challenge for RNNs. Motivated by advances in training
deep neural networks (DNNs) and the availability of large
datasets, we seek an approach that is able to: (1) effectively
model the irregular heterogeneous data; (2) parse the under-
lying complex nonlinear dependency among heterogeneous
data; (3) joint learning and scale up numbers of different data
domains.
Currently, some efforts have been made to embed hetero-
geneous data into the same feature space, but the embed-
ding layers are usually used to extract the domain-invariant
features. Inspired by the success of adversarial strategy on
domain adaption (Ajakan et al. 2014; Ganin et al. 2016;
Bousmalis et al. 2016), we use adversarial strategy to make
sure the shared layers extract domain-specific features which
are suitable for each data domain. Specifically, we propose a
domain-adversarial extractor and regard domain-adversarial
learning as a classification task. Finally, each type of data
are embedded with domain-specific features and fed into
next stage, then the dependency among heterogeneous data
is modeled for knowledge sharing. Compared to the vanilla
convolutional neural networks (CNNs) or hybrid models that
combine CNNs and RNNs, our proposed framework extends
it by joint learning the representations of heterogeneous data
under a domain-adversarial multi-task framework.
We conduct experiments on heterogeneous data of many
FDA-approved drugs and purpose-unknown compounds.
The results on five evaluation metrics (Hamming Loss,
One Error, Coverage, Ranking Loss, and Average Precision)
prove that our method holds the great promise to identity
the purpose of small molecule compounds more accurately.
Moreover, we predict novel therapeutic properties for more
than 3,000 unidentified compounds, and the prediction re-
sults are partly reported by other researches. As a highly ex-
tensible method, our framework can integrate various data
beyond the three domains examined here.
In the paper, our main contributions are:
• We approach the purpose prediction of small molecule
compounds problem as a representation learning task
based on drug-informatics data that are from different do-
mains. To our knowledge, this is the first time to predict
novel therapeutic properties of both extensive purpose-
unknown compounds and FDA-approved drugs by multi-
task learning with adversarial strategy.
• We design a domain-adversarial extractor for learning
domain-specific features of heterogeneous data. Then our
proposed framework joint learns representation for inte-
grating multiple domain knowledge. Eventually, five eval-
uation metrics are used to assess the performance of pro-
posed framework in its entirety.
• We conduct experiments of real-world data (including
drug physiochemical property, drug fingerprint, and drug
perturbation gene expression) on the task of novel thera-
peutic property prediction. By the conclusion of training
on the real-world existing date, promising results prove
the effectiveness of our proposed framework over com-
petitive baselines, and novel properties of compounds we
predicted are mostly in line with their patents.
Table 1: Mathematical Notations
Symbol Description
X: xi ∈X, #{X}=m;
Y: yi ∈Y, yi ∈ Rq;
indices and number of data;
indices and number of classes;
F: f i ∈F,
f i = {f i0, f i1,.., f ik },
f ij = (Value, Type);
feature space,
each datum has a feature set,
each feature element consists
of value and type;
ex
i
= {efij |j ∈k}; embedding vectors;
E(f i)={E(f ij)|j ∈k},
LExt(θExt, X);
functions for domain-specific
extractor;
C(xi) = C(f i),
LCls(θCls, X);
functions for classification;
Problem Definition
In this research, we integrate heterogeneous data, which
means each data corresponds to several kinds of features,
to predict therapeutic properties of purpose-unknown com-
pounds and repurpose novel therapeutic properties of FDA-
approved drugs. The whole framework consists of two
stages. Learning target representation for each kind of fea-
ture in the first stage is modeled as a multi-class classifica-
tion task when each feature type is encoded as one-hot vec-
tors. In the second stage, therapeutic property prediction for
each data is regarded as one multi-label classification task
according to known uses of small molecule compounds, and
the number of known uses can be at least one. Some symbols
and descriptions of tasks as in Table 1.
Proposed Method
In this section, we discuss the whole framework (as shown
in Fig. 2), including the heterogeneous data embedding,
domain-adversarial extractor for more specific domain in-
formation, and joint learning under multi-task framework.
•••••• 
Domain-adversarial
Extractor
Data
Embedding
Convolutional Neural Network
•••••• 
Multi-label Classification
Recurrent Neural Network
•••• 
Stage I
Stage II
Multi-Class Classification
Figure 2: The training for the whole framework consists of
two stages. Stage I is a multi-class classification task for ex-
tracting domain-specific features, and Stage II is a multi-
label classification task for integrating knowledge of multi-
ple domains under the multi-task framework.
First of all, fix-sized feature vectors are generated from
different domains by embedding, during which a domain-
adversarial extractor is utilized to extract more domain-
specific information. Then we integrate shared knowledge
from multiple domains by regarding each class as a single
binary classification task. Accordingly, we combine stages
as an ensemble, as defined in Equation (1), to address the
challenge of novel therapeutic property prediction of small
molecule compounds under a domain-adversarial multi-task
framework.
argmin
θ
L(θ;X) = LExt(θExt, X) + LCls(θCls, X) (1)
Heterogeneous Data Embedding
CNNs are well-known deep learning architecture for encod-
ing input with arbitrary size in a sliding-window manner,
and the DeepSEA successfully applied CNNs to sequence-
based problems in genomics (Zhou and Troyanskaya 2015).
There are 6 layers before classification in the entire ar-
chitecture, including 3 convolutional layers (320, 480, and
960 convolutional kernels individually), 2 max pooling lay-
ers, and 1 fully connected (FC) layer. DeepSEA predicts
chromatin features after training with large-scale chromatin-
profiling data from the ENCODE project (Consortium and
others 2012).
Owing to its outstanding performance on genomic se-
quences, we simplify original architecture for embedding
heterogeneous data that have various feature patterns. As
shown in Fig. 3, the basic feature extractor of CNN are
Input with Arbitrary Size
Kernel size 1ⅹ8
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Kernel size 
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→
→
8 Feature Maps
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→
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→
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Kernel →
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Figure 3: CNN architecture. A CNN mainly consists of three
parts: convolutional layers, max pooling layers, and fully
connected layers. In this paper, we use RoI pooling layer
instead of fully connected layers to extract fixed-length fea-
ture vector from the feature maps.
stacked by convolution operations with different number of
kernels and max pooling layers, then the fully connected
layer has been replaced by region of interest (RoI) pooling
layer to generate fixed dimensional embedding vectors (Gir-
shick 2015). On the one hand, the capacity of learning more
abstract patterns could be guaranteed by each convolutional
layer, and the receptive field of top layer should be smaller
than original sequence. On the other hand, the number of
parameters from full connected layers accounts for about
80% in whole neural network, they will enlarge the model
size and slow down the model training. So both reduction
for number of convolutional kernels and RoI pooling layer
as substitution bring several benefits, especially decreasing
overfitting risk.
Domain-Adversarial Extractor
To learn target representations, we assume that embedding
vectors are classified accurately about which type they be-
long to if they consist of more differences. Because in
our area, data are heterogeneous with different feature pat-
terns and describing different attributes, due to various data
sources. For instance, drug physiochemical property are
from JoeLib, OpenBabel and Chemminer chemoinformat-
ics databases; drug fingerprints are from PubChem Com-
pound database; and drug perturbation gene expression are
from L1000 database of LINCS project. Each type of fea-
ture contains similar and different characters. Although het-
erogeneous data are transformed into the same feature space
after embedding, there is commonly no guarantee to keep
more domain-specific information.
p(·|efij ) = Softmax(WThX + b) (2)
Difference Similarity Difference Similarity
without Domain-specific Extrctor
with Domain-specific Extrctor
Few Knowledge Sharing
Miss-
classification
Domain Knowledge Intergration
Figure 4: Domain-adversarial learning. The inefficient fea-
ture extraction leads to too much similar information in vec-
torial representations for many existing approaches. But af-
ter domain-specific extractor gets fully trained, the domain-
invariant redundancy is reduced effectively.
Inspired by every single type of data is important
in its own way and provides different views of multi-
ple domains, we devise a domain-adversarial extractor to
make heterogeneous data provide domain-specific instead
of domain-invariant information for integration. During
domain-adversarial learning, each type of feature is ex-
tracted with more individual private characters that represent
special domain knowledge. Otherwise, the shared layers pay
more attention to similarities which introduce redundancy
for embedding (as shown in Fig. 4). Specifically, given an
embedding vector ef
i
j , we use a Softmax model which intro-
duces adversarial competition among classes to compute the
probability p(·|efij ) over all features, as defined in Equation
(2). After domain-adversarial extractor gets fully trained, the
pre-trained model is regarded as prior knowledge for learn-
ing in the next stage.
Joint Learning under Multi-task Framework
As an extension of RNNs, bidirectional LSTM (Bi-LSTM)
is a strong and trainable sequence model. In this paper, it is
a special case for Bi-LSTM to integrate all heterogeneous
data by regarding each of them as an input in one time step,
because there is no temporal extension for all features. At
meantime, the dependency among different types of features
is parsed over the positive time and negative time direction,
as defined in Equation (3). Finally, Bi-LSTM incorporates
information and transfers embedding vectors into high-level
representations by concatenating two final states, as shown
in Fig. 5.
ht =
−→
h t ⊕←−h t
= Bi-LSTM(ex
i
,
−→
h t−1,
←−
h t+1, θCls)
(3)
where
−→
h t and
←−
h t are the hidden states at time t of the for-
ward and backward LSTMs respectively;⊕ is concatenation
operation; θ denotes all parameters in Bi-LSTM.
•••••• 
Bidirectional
LSTM
Backward
Cell
Forward
Cell
Backward Output Forward Output
•••••• 
S0 S1 S2 St•••••• S3 St-1
•••••• 
Figure 5: Bi-LSTM architecture. Bi-LSTM can be trained
using all available information in both forward and back-
ward direction. Last, binary classifiers share knowledge with
each other to make model joint learn representations under
the multi-task framework.
LCls(θCls, X) =max(C(X), 0)− C(X)× Y
+ log(1 + exp(− | C(X) |)) (4)
To learn joint representations of heterogeneous data, we
build a multi-task framework for all classes. Specifically,
target prediction is formulated as a multi-label classification
problem, and each of class is regarded as related binary clas-
sification simultaneously under the multi-task framework.
Because the information coming from the training signals
of related tasks are inevitably ignored by ensembling sepa-
rated models. Then the Bi-LSTM is trained with objective
function of sigmoid cross entropy, as defined in Equation
(4), resulting in effective knowledge sharing under the multi-
task framework for novel therapeutic property prediction of
compounds.
Experiments
Data Description
We set up two datasets for evaluating our model. The first
one contains three domain-specific FDA-approved drugs
(TDF) of 6,025 samples representing 637 FDA-approved
drugs. Another one contains three domain-specific unidenti-
fied compounds (TDU) of 3,749 samples representing 3,749
unidentified compounds. Three domain-specific data record
drug perturbation gene expression level, structural finger-
print, and physicochemical property separately. The details
as following:
Drug Perturbation Gene Expression: from L1000
database of LINCS project, we extract Z-scores of gene ex-
pression data when FDA-approved drugs and as yet purpose-
unknown compounds are exposed in five typical cell lines
(A375, HA1E, HT29, MCF7, and PC3). In TDF, we re-
gard gene expression data stimulated by compounds with
different doses and times as different samples, amounting to
6,025 transcriptional expression samples for each cell line.
In TDU, we combined gene expression data stimulated by
different dose of compounds by a weighted average way in-
troduced by Subramanian A et al (Subramanian et al. 2017).
Drug Fingerprint: the structure data in SDF format are
from PubChem Compound database and used to calcu-
late the fingerprint vector of each drug (Kim et al. 2015;
Cao et al. 2008). Features in this domain represent chemical
structure of these compounds. In TDF, we replicate the fin-
gerprint vector for the same FDA-approved drugs to match
each sample of gene expression domain. In TDU, each fin-
gerprint vector represents a unique purpose-unknown com-
pound.
Drug Physicochemical Property: the JoeLib, OpenBa-
bel and Chemminer chemoinformatics databases provide the
information to calculate the physicochemical property and
chemical descriptor of compounds. Features in this domain
represent the chemical and physical properties, such as the
molecular weight, polar surface area, etc. In TDF, we repli-
cate the physicochemical property vector for the same FDA-
approved drugs to match each sample of gene expression
domain. In TDU, each physicochemical property vector rep-
resents a unique purpose-unknown compound.
The first level of drug ATC codes, which indicate drug
therapeutic properties, is used to label each drug sample.
Notably, each drug has no less than one ATC labels (A: ali-
mentary tract and metabolism; B: blood and blood-forming
organs; C: cardiovascular system; D: dermatologicals; G:
genito-urinary system and sex hormones; H: systemic hor-
monal preparations, excluding sex hormones and insulins;
J: anti-infectives for systemic use; L: anti-neoplastic and
immunomodulating agents; M: musculoskeletal system; N:
nervous system; P: anti-parasitic products; R: respiratory
system; S: sensory organs; and V: several others). The ATC
labels are mostly obtained from the records of DrugBank
database (Wishart et al. 2017), and the rest of them are ob-
tained from PubChem Compound database.
Training and Evaluation Settings
In this paper, the whole multi-task framework is trained over
two stages using Dataset 1. The first stage is to make CNN
extract domain-specific features. Thus, we discriminately
pre-trained the CNN based on randomly initialized param-
eters by introducing adversarial competition among several
feature types. Once domain-specific features are extracted,
the performance of Softmax model nearly matches our as-
sumption that feature types can be classified accurately.
In the second stage, we apply Bi-LSTM to model under-
lying nonlinear dependency existing among heterogeneous
data based on domain-specific feature vectors. Followed by
a multi-label classification layer which consists of multi-
ple binary classifiers corresponding to each class. So during
the training procedure of Bi-LSTM, the CNN also get fur-
ther optimization and all classes joint learn representation
by sharing the specific domain knowledge. As a result, the
prediction performance gets further improvement on several
multi-label classification evaluation metrics (as defined in
Equation 5∼9) (Schapire and Singer 2000).
(1) Hamming Loss: evaluates how many times an
instance-label pair is misclassified, i.e. a label not belong-
ing to the instance is predicted or a label belonging to the
instance is not predicted. The performance is perfect when
hamming loss equals to 0; the smaller the value of hamming
loss, the better the performance.
HammingLoss =
1
m
m∑
i=1
1
q
∣∣C(xi)4 yi∣∣ (5)
(2) One Error: evaluates how many times the top-ranked
label is not in the set of proper labels of the instance. The
performance is perfect when one error equals to 0; the
smaller the value of one error, the better the performance.
OneError =
1
m
m∑
i=1
[[[argmax
yˆ∈Y
C(xi, yˆ)] /∈ yi]] (6)
(3) Coverage: evaluates how far we need, on the average,
to go down the list of labels in order to cover all the proper
labels of the instance. It is loosely related to precision at the
level of perfect recall. The smaller the value of coverage, the
better the performance.
Coverage =
1
m
m∑
i=1
max
yˆ∈yi
rank[C(xi, yˆ)]− 1 (7)
(4) Ranking Loss: evaluates the average fraction of label
pairs that are reversely ordered for the instance. The perfor-
mance is perfect when ranking loss equals to 0; the smaller
the value of ranking loss, the better the performance.
RankingLoss =
1
m
m∑
i=1
1
|yi||yi| ·#{(yˆj , yˆk)|
C(xi, yˆj) ≤ C(xi, yˆk), (yˆj , yˆk) ∈ yi × yi}
(8)
where yi denotes the complementary set of yi in Y.
(5) Average Precision: evaluates the average fraction of
labels ranked above a particular label y ∈ Y which actually
are in Y. It is originally used in information retrieval (IR)
systems to evaluate the document ranking performance for
query retrieval. The performance is perfect when average
precision equals to 1; the bigger the value of average pre-
cision, the better the performance.
AveragePrecision =
1
m
m∑
i=1
1
|yi|
∑
yˆ∈yi
#{y′|rank[C(xi, y′)] ≤ rank[C(xi, yˆ)], y′ ∈ yi}
rank[C(xi, yˆ)]
(9)
Table 2: Mean Performance Comparisons Across Methods.
Hamming Loss↓ One Error↓ Coverage↓ Ranking Loss↓ Average Precision↑
RF
Gene expression 0.3438 0.6238 3.0347 0.2051 0.5479
Linear combination 0.3261 0.5809 2.7822 0.1865 0.5786
Physicochemical property 0.0785 0.4307 1.8003 0.11 0.7011
GBDT
Gene expression 0.1116 0.5314 3.1914 0.2132 0.5971
Linear combination 0.1541 0.3581 1.9703 0.118 0.7357
Physicochemical property 0.0383 0.2228 1.2558 0.0697 0.8346
RF AE 0.3035 0.3812 1.5528 0.0904 0.7363PCA 0.3533 0.6073 2.6634 0.1788 0.5777
GBDT AE 0.0539 0.1436 1.1287 0.0588 0.8814PCA 0.0779 0.1419 1.0182 0.0499 0.8865
CNN 0.0807 0.9356 0.9637 0.5154 0.3342
CNN + Bi-LSTM 0.0153 0.0809 0.3086 0.0135 0.9499
CNN + Bi-LSTM
(Domain-specific extractor) 0.0083 0.0479 0.2244 0.0072 0.9710
Comparing Methods
As we introduced above, different feature extraction meth-
ods have the huge impact on prediction performance. So
we compare our framework to other methods with different
schemes for extracting different level representations.
The following feature extraction schemes are adopted:
Linear Combination: rather than information loss during
learning abstract features, directly linear combination can
maintain fully original information;
Principal Component Analysis (PCA): to retain key fea-
tures in original data and avoid compressing data too much
by PCA, at least 99% variance is guaranteed to be retained
for each type of feature;
Autoencoder (AE): for extracting more representative
features, we build an autoencoder by stacking two layers,
and each layer is trained in unsupervised manner.
The following models are adopted for comparisons:
Random Forest (RF): as a classical robust ensemble
classifier, RF has capacities to eliminate the disadvantage of
instability for the decision tree and cope with large feature
space. In this study, the dimension of all original data is over
10,000;
Gradient Boosting Decision Tree (GBDT): produces a
prediction model in the form of an ensemble of weak pre-
diction models, and optimizes a cost function over func-
tion space by iteratively choosing a function (weak hypothe-
sis) that points in the negative gradient direction. Especially
there are 7 feature sources from 3 data domains, and the tar-
get prediction task is imbalanced labeled in this paper;
CNN: owing to its performance of dealing with arbitrary
sized data, we optimize the architecture of DeepSEA to
embed heterogeneous data. Followed by logistic regression
(LR) for multiple binary classifications;
Hybrid Model: the combination of CNN and Bi-LSTM
can not only map heterogeneous data into the same feature
space, also model the dependency automatically.
Performance Assessment
Table.2 shows the hamming loss, one error, coverage, rank-
ing loss, and average precision of different methods.
Experiments on several data domains. Firstly, to eval-
uate the effect of knowledge sharing for prediction task, we
use RF and GBDT on only drug physicochemical property
(80 dimensions), only gene expression (12328 dimensions),
and the linear combination of both (12408 dimensions).
While the integration of two domains does not contribute to
the final performance generally. For example, although the
performance of RF on gene expression gets improvement by
integration, the results on the only physicochemical property
are still best. As well as the results of GBDT show the same
tendency. It turns out that inefficient domain integration de-
creases the performance resulting from the feature patterns
vary significantly. All results for different number of data
domains are shown in Supplementary Table 1.
Experiments on different feature extraction schemes.
Secondly, to extract different level features and explore the
underlying nonlinear dependency among all heterogeneous
data. PCA is adopted for selecting key features. AE and
CNN are responsible for learning high level features. Then
features are appended together and regarded as input of
models. From these comparisons, the hybrid model with Bi-
LSTM that is capable of modeling dependency among het-
erogeneous data leads to accurate prediction, which proves
nonlinear dependency has better prospect for inference.
Experiments on domain-specific extraction. Eventu-
ally, in order to promote domain knowledge integration, we
devised domain-specific extractor to reduce the redundancy
inside heterogeneous data. Specifically, we utilize the adver-
sarial strategy in common layers of embedding to make each
feature type be classified accurately. Then, Bi-LSTM models
the dependency among domain-specific features under the
framework of multi-task learning. As a result, all evaluation
metrics of our framework get the further improvement ow-
ing to domain-specific extractor provides prior knowledge
and optimizes the searching space.
Table 3: Patents of 10 Predicted Compounds
BRD ID PubChem CID Patent ID
BRD-K08132273 2062 US2015018301
BRD-K64341947 9844347 US2016324856
BRD-K87696786 9926999 US2013035335
BRD-K76304753 8691 US2009227606
BRD-A26032986 65909 US6406716
BRD-K38003476 5282493 US2016263173
BRD-K67537649 9549305 US6699879
BRD-A75552914 20507134 US8168629
BRD-A78942461 3682 US8716350
BRD-A35519318 656667 US9517221
Purpose Prediction of Purpose-unknown Small
Molecule Compounds
Having demonstrated the multi-task framework’s ability to
effectively extract features and to integrate data from dif-
ferent domains, we investigate whether the framework can
identify novel purpose of compounds without a definite ther-
apeutic property. By applying the framework to heteroge-
neous data of 3,749 purpose-unknown small molecule com-
pounds in TDU, at least one ATC labels for 2,855 com-
pounds are predicted. To further address whether these pre-
dictions are reliable, we visualize the activated and inte-
grated features of the final layer in two dimensions using t-
distributed stochastic neighbor embedding (t-SNE) for both
FDA-approved drugs and purpose-unknown compounds (As
shown in Fig. 6a) (Maaten and Hinton 2008). The regions
occupied by purpose-unknown compounds are covered by
FDA-approved drugs with the same ATC label. For instance,
14 purpose-unknown compounds in the Example Cluster are
predicted for nervous system indications. And the patents
of 10 compounds are related to nervous system (as shown
in Table 3 and Supplementary Table 2). We find that the
purpose-unknown compounds are significantly closer to the
FDA-approved drugs which have the same ATC labels than
to others (Mann-Whitney test, P Value < 0.0001, Fig. 6b).
FDA-approved Drugs Repositioning
The experimental results also show that our framework
can identify novel therapeutic properties of FDA-approved
drugs, namely drug repositioning. And 18 repurposed drugs
have been reported or brought to the clinics, listed in a
database named RepurposeDB (Shameer et al. 2017). For
example, mecamylamine (PubChem Compound ID: 4032),
the first orally available antihypertensive agent, is predicted
for nervous system indications. Recent researches and clini-
cal trials demonstrated that mecamylamine is very effective
for anti-depression and anti-addictive (Lippiello et al. 2008;
Shytle et al. 2002). Moreover, in the t-SNE projection,
mecamylamine is significantly closer to nervous systems
drugs than to others (Mann-Whitney test, P Value < 0.0001,
Fig. 6c).
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Figure 6: Identifying novel therapeutic properties of FDA-
approved and purpose-unknown compounds. (a) Compari-
son of purpose-unknown compounds (hollow triangle) with
FDA-approved drugs (solid circle) based on t-SNE projec-
tion of features in the final layer. (b) Group A is the two-
dimensional projection distance between purpose-unknown
compounds with the corresponding FDA-approved drugs
whose ATC is the same as predicted labels, and Group B
is the distance among purpose-unknown compounds with
other FDA-approved drugs whose ATC is different from pre-
dicted labels. (c) Group A is the two-dimensional projec-
tion distance between mecamylamine with nervous systems
drugs, and Group B is the distance between mecamylamine
with other FDA-approved drugs that are not nervous systems
drugs.
Conclusion
In this paper, we propose a domain-adversarial multi-task
framework for joint learning representations of heteroge-
neous data to predict the potential purpose of small molecule
compounds. Our framework can adaptively fit the data from
different domains by utilizing adversarial strategy to extract
domain-specific features and modeling the nonlinear depen-
dency among heterogeneous data. Experimental results with
real-world drug-informatics data prove the effectiveness of
our proposed framework over competitive baselines. And as
a highly extensible framework, our framework can be ap-
plied to various attributes beyond the three domains showed
here. More importantly, the novel therapeutic properties of
compounds we predicted stay in step with their patents, il-
lustrating the effectiveness of our framework in the industry
for screening the purpose of huge amounts of unidentified
compounds in a fast and precise manner.
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